Page 3 - Wakefulness Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Wakefulness Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Wakefulness Test Today - Breaking & Trending Today

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK861 an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Published: February 9, 2024

Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.

Source: businesswireindia.com

Related Topics:

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonis

Published: February 9, 2024

− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial− TAK-861 Was Found to be Generally Safe and Well-Tolerated− Results Will be Presented at an Upcoming Scientific CongressOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu...

Source: pharmiweb.com

Related Topics:

United States Yuko Yoneyama Upcoming Scientific Congress Takeda Pharmaceutical Company Limited Exchange Commission Key Secondary Endpoints Were Met Narcolepsy Type Generally Safe Results Will Upcoming Scientific Wakefulness Test Annual Report

Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study - Takeda Pharmaceutical (NYSE:TAK)

Published: February 9, 2024

Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.

Source: benzinga.com

Related Topics:

Takeda Pharmaceutical Co Ltd Wakefulness Test